David J. C.
Constable
a,
Alan D.
Curzons
b,
Luisa M.
Freitas dos Santos
c,
Graham R.
Geen
*c,
Robert E.
Hannah
d,
John D.
Hayler
e,
John
Kitteringham
c,
Michael A.
McGuire
d,
John E.
Richardson
e,
Paul
Smith
c,
R. Lee
Webb
d and
Marvin
Yu
d
aGlaxoSmithKline, 2200 Renaissance Boulevard, King of Prussia, PA 19406, USA
bGlaxoSmithKline, Southdownview Way, Worthing, West Sussex, UK BN14 8NQ
cGlaxoSmithKline, New Frontiers Science Park, Third Avenue, Harlow, Essex, UK CM19 5AW. E-mail: graham_geen-1@gsk.com
dGlaxoSmithKline, 709 Swedeland Road, King of Prussia, PA 19406, USA
eGlaxoSmithKline, Old Powder Mills, near Leigh, Tonbridge, Kent, UK TN11 9AN
First published on 31st January 2001
A set of metrics has been developed which enables a simple assessment to be made of batch processes in terms of waste, energy usage, and chemistry efficiency. It is intended to raise awareness of green chemistry by providing a tool to assist chemists in monitoring progress in the reduction of environmental impact as they design new routes and modify processes.
Green ContextThe development of a set of simple measurements which help to assess the environmental impact of a chemical process is described. The impact of such an approach on both defining real areas for improvement, and highlighting the importance of green chemistry as an integral process development tool is highlighted.DJM |
We wished to introduce a set of measures that would enable an assessment of the initial development process and allow environmental improvements to be monitored during the development stages. It was also intended that these measures would raise the awareness of green chemistry,1,2 highlight key issues and provide information that would assist chemists in choosing between alternative routes. We required a relatively simple template that could be completed using readily obtainable information such as that found in typical process description reports. This information would also need to tie in with the comprehensive environmental review already conducted on compounds in the later stages of development and align with the GlaxoSmithKline Design for the Environment programme.3
The measures are a mixture of qualitative and quantitative assessments of inputs and outputs for a particular process.4 The latter is a refinement of the E-factor proposed by Sheldon.5 Although designed specifically for use within the company, these measures should find wider relevance within the pharmaceutical and chemical industries.6
Example of the difference between a stage and a step: This may be achieved in one stage, but has three chemistry steps. 1. Reduction of nitro group 2. Reduction of aromatic ring 3. Hydrochloride salt formation
Although these numbers do not provide information on waste stream composition, they provide enough information to prompt the chemist to explore opportunities for mass reduction and recycling, and to consider the potential environmental impact of the waste.
Typically, significant reductions in volumes of solvent, aqueous and input materials are experienced as more efficient routes to target compounds are introduced and optimised. An actual example of this progress is illustrated in Fig. 1.
Fig. 1 |
We have found that it normally takes no more than 1–2 hours to complete the first template for a compound. Subsequent updates may be completed more quickly. It is important to emphasise that while these measures give a broad view of the likely environmental impact of the process, the information derived is limited. In particular, the system does not provide a breakdown of the composition of waste streams, nor does it address treatment options, or the acquisition of raw materials from sustainable sources. Key inputs to the design of the process from the process engineering and safety testing groups are also outside the scope of the current system. When processes are transferred to a manufacturing plant, it is also essential that a full environmental assessment is undertaken and this must be completed prior to the preparation of validation batches.
The introduction of the set of measures described here has raised the environmental awareness of our process chemists and has enabled us to document and highlight improvement opportunities. These opportunities will help move GlaxoSmithKline towards achieving the ultimate target of drug manufacture using ‘green chemistry’. It will also enable a direct comparison of the potential environmental impact of alternative routes for a particular compound as well as between different compounds.
This journal is © The Royal Society of Chemistry 2001 |